Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8+ activation
Open Access
Abstract
No abstract availableKeywords
Funding Information
- ShanghaiTech University (B16F10)
- National Natural Science Foundation of China (32270991)
- National Natural Science Foundation of China (32100751)
- National Natural Science Foundation of China (82430089)
- National Natural Science Foundation of China (32100123)
- Chinese Academy of Sciences
- Shanghai Municipal Health Commission (20214Y0510)
This publication has 52 references indexed in Scilit:
- Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident TregsCancer Immunology, Immunotherapy, 2024
- Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapyCancer Cell, 2024
- Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibodyClinical and Experimental Medicine, 2024
- Tumor-infiltrating regulatory T cells as targets of cancer immunotherapyCancer Cell, 2023
- Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsCancer Cell, 2022
- Clinical Challenges of Immune Checkpoint InhibitorsCancer Cell, 2020
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesCancer Cell, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organCancer Immunology, Immunotherapy, 2010
- NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal AntibodiesCellular Immunology, 1998